What it is
Survodutide is a dual agonist: one engineered peptide that activates both the GLP-1 receptor and the glucagon receptor. In the trial record it is called BI 456906. Zealand Pharma discovered it; Boehringer Ingelheim is developing it.
The pairing is deliberate. GLP-1 activation reduces appetite and improves blood-sugar control. Glucagon activation raises energy expenditure and acts directly on the liver. Glucagon alone would also raise blood sugar — the GLP-1 half is what makes the combination workable.
What the programme is actually testing
A striking share of the survodutide programme is aimed at the liver rather than the scales: metabolic dysfunction-associated steatohepatitis, the condition in which fat accumulation in the liver progresses to inflammation and scarring.
That follows directly from the mechanism. Adding glucagon-receptor activity to a GLP-1 drug is, among other things, a way of acting on the liver, and the development programme reflects that reasoning rather than treating weight as the only endpoint. It is a genuine difference from the pure GLP-1 drugs, and it is the most interesting thing about the compound.
Where it stands
Checked on ClinicalTrials.gov, 2026-09-09:
| Count | |
|---|---|
| Registrations naming survodutide | 26 |
| Lead sponsor Boehringer Ingelheim | 25 |
| Any other sponsor | 1 (University Medical Center Groningen) |
| Phase 3 registrations | 9 |
| Participants across phase 3 | 11,801 |
And on DailyMed the same day: no records at all. There is no US label for survodutide, which means no approved indication, no dose, no contraindications, no warnings — none of the content a regulator produces after reviewing a programme like the one above.
PubMed indexed 77 records. A big registry and a thin literature is the ordinary shape of a drug still inside development.
The comparison this library can make
Survodutide and the compound developed in China as mazdutide are the two GLP-1/glucagon dual agonists here. Their pharmacology is closely related. Their evidence is not:
- Survodutide — 26 registrations, 25 of them from the developer. One outside study, from a Dutch university hospital.
- Mazdutide — 41 registrations from fifteen sponsors, more than a dozen filed by hospitals and universities on their own account.
Neither fact says which drug works better. What it says is how many independent parties have looked. Survodutide is closer to the norm in this library, where the amylin analogue has 43 registrations from a single sponsor and the triple agonist LY3437943 32 of 33 from one company.
Where it sits in the family
- Semaglutide — GLP-1 only; the one with a long approved-label history.
- Tirzepatide — GLP-1 and GIP; approved.
- Survodutide — GLP-1 and glucagon; not approved.
- Mazdutide — GLP-1 and glucagon; not approved.
- The one that engages all three receptors — not approved.
- Cagrilintide — amylin, a separate hormone family.
- Orforglipron — GLP-1 only, and not a peptide at all; an oral small molecule in phase 3.
The only two in that list a regulator has reviewed are the first two. Everything below them is being sold on the strength of trial arms.
One name that belongs nowhere on that list, despite being searched alongside every entry on it: glucagon-like peptide 3. Humans do not make one — the proglucagon precursor stops at GLP-2 — and the searches almost always mean a molecule acting at three receptors rather than a third hormone.